Slingshot members are tracking this event:

Ziopharm (ZIOP) Announces Interim Phase 1 Results Assessing Ad-RTS-hIL-12 + Veledimex in Patients with Recurrent Brain Cancer at the 21st Annual Scientific Meeting of the Society for Neuro-Oncology

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

Slingshot Insights Explained
Catalyst Date
Occurred on:
Nov 17, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Interim Results, Phase 1, Ad-rts-hil-12, Veledimex, Recurrent Brain Cancer, Society For Neuro-oncology, Annual Scientific Meeting